Opioid modulation of immune responses: Effects on phagocyte and lymphoid cell populations

Journal of Neuroimmunology

Volumn 83, Issue 1-2, 1998, Pages 36-44

  Eisenstein, Toby K ^a   Hilburger, Mary E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune responses; Immunomodulation; Macrophages; Morphine; Opioids; Phagocytes

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ARACHIDONIC ACID DERIVATIVE; CHEMOTACTIC FACTOR; CYTOKINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MITOGENIC AGENT; MORPHINE; NALOXONE; OPIATE; OPIATE AGONIST; T LYMPHOCYTE ANTIGEN;

ARTICLE; B LYMPHOCYTE; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOID CELL; MACROPHAGE; MONKEY; MONONUCLEAR CELL; NATURAL KILLER CELL; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; RODENT; T LYMPHOCYTE;

HUMANS; LYMPHOCYTES; MACROPHAGES; MORPHINE; NARCOTICS; NEUROIMMUNOMODULATION; PHAGOCYTES;

EID: 0032520733     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00219-1     Document Type: Article

References (100)

1. Adler M.W., Geller E.B., Rosow C.E., Cochin J. The opioid system and temperature regulation. Ann. Rev. Pharmacol. Toxicol. 28:1988;429-449.
2. Alicea C., Belkowski S., Eisenstein T.K., Adler M.W., Rogers T.J. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the κ-opioid agonist U50,488H. J. Neuroimmunol. 64:1996;83-90.
3. Arora P.K., Fride E., Petitto J., Waggie K., Skolnick P. Morphine-induced immune alterations in vivo. Cell. Immunol. 126:1990;343-353.
4. Band L.C., Pert A., Williams W., de Costa B.R., Rice K.C., Weber R.J. Central μ-opioid receptors mediate suppression of natural killer cell activity in vivo. Prog. Neuroendocrinimmunol. 5:1992;95-101.
5. Bayer B.M., Daussin S., Hernandez M., Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid-dependent mechanism. Neuropharmacology. 29:1990;369-374.
6. Bayer B.M., Gastonguay M.R., Hernandez M.C. Distinction between the in vitro and in vivo inhibitory effects of morphine on lymphocyte proliferation based on agonist sensitivity and naltrexone reversibility. Immunopharmacology. 23:1992;117-124.
7. Belkowski S.M., Alicea C., Eisenstein T.K., Adler M.W., Rogers T.J. Inhibition of IL-1 and TNF-α production following treatment of macrophages with the kappa opioid agonist U50,488H. J. Pharmacol. Exp. Ther. 273:1995;1491-1496.
8. Belkowski S.M., Zhu J., Liu-Chen L.Y., Eisenstein T.K., Adler M.W., Rogers T.J. Sequence of κ-opioid receptor cDNA in the R1.1 thymoma cell line. J. Neuroimmunol. 62:1995;113-117.
9. Belkowski, S.M., Zhu, J., Liu-Chen, L.Y., Eisenstein, T.K., Adler, M.W., Rogers, T.J., 1995c. Detection of κ-opioid receptor mRNA in immature T cells. In: Sharp, B., Eisenstein, T., Madden, J., Friedman, H. (Eds.), The Brain Immune Axis and Substance Abuse. Plenum, New York, pp. 11-16.
10. Bhargava H.N., Thomas P.T., Thorat S., House R.V. Effects of morphine tolerance and abstinence on cellular immune function. Brain Res. 642:1994;1-10.
11. Bidlack, J.M., Hemmick, L.M., 1990. Morphine enhancement of mitogen-induced T-cell proliferation. International Narcotics Research Conference, pp. 405-408, (Abstract).
12. Bocchini G., Bonanno G., Canevari A. Influence of morphine and naloxone on human peripheral blood T-lymphocytes. Drug Alcohol Depend. 11:1983;233-237.
13. Bryant H.U., Bernton E.W., Holaday J.W. Immunosuppressive effects of chronic morphine treatment in mice. Life Sci. 41:1987;1731-1738.
14. Bryant H.U., Bernton E.W., Holaday J.W. Morphine pellet-induced immunomodulation in mice: temporal relationships. J. Pharmacol. Exp. Ther. 245:1988;913-920.
15. Bryant H.U., Roudebush R.E. Suppressive effects of morphine pellet implants on in vivo parameters of immune function. J. Pharmacol. Exp. Ther. 255:1990;410-414.
16. Bussiere J.L., Adler M.W., Rogers T.J., Eisenstein T.K. Differential effects of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol. Immunotoxicol. 14:1992;657-673.
17. J (beige) mice. Life Sci. 52:1992;PL43-PL48.
18. Bussiere J.L., Adler M.W., Rogers T.J., Eisenstein T.K. Cytokine reversal of morphine-induced suppression of the antibody response. J. Pharmacol. Exp. Ther. 264:1993;591-597.
19. Carpenter G.W., Garza H.H. Jr., Gebhardt B.M., Carr D.J.J. Chronic morphine treatment suppresses CTL-mediated cytolysis, granulation, and cAMP responses to alloantigen. Brain Behav. Immun. 8:1994;185-203.
20. Carpenter G.W., Carr D.J.J. Pretreatment with β-funaltrexamine blocks morphine-mediated suppression of CTL activity in alloimmunized mice. Immunopharmacology. 29:1995;129-140.
21. Carr D.J.J., France C.P. Immune alterations in morphine-treated Rhesus monkeys. J. Pharmacol. Exp. Ther. 267:1993;9-15.
22. 1. Life Sci. 49:1991;45-51.
23. Carr D.J.J., Gebhardt B.M., Paul D. Alpha-adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity. J. Pharmacol. Exp. Ther. 264:1993;1179-1186.
24. Carr D.J.J., Gerak L.R., France C.P. Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. J. Pharmacol. Exp. Ther. 269:1994;693-698.
25. Carr D.J.J., Mayo S., Gebhardt B.M., Porter J. Central α-adrenergic involvement in morphine-mediated suppression of splenic natural killer cell activity. J. Neuroimmunol. 53:1994;53-63.
26. Casellas A.M., Guardiola H., Renaud F.L. Inhibition by opioids of phagocytosis in peritoneal macrophages. Neuropeptides. 18:1991;35-40.
27. Chao C.C., Hu S., Molitor T.W., Zhou Y., Murtaugh M.P., Tsang M., Peterson P.K. Morphine potentiates transforming growth factor-β release from human peripheral blood mononuclear cell cultures. J. Pharmacol. Exp. Ther. 262:1992;19-24.
28. Chao C.C., Molitor T.W., Close K., Hu S., Peterson P.K. Morphine inhibits the release of tumor necrosis factor in human peripheral blood mononuclear cell cultures. Int. J. Immunopharmacol. 15:1993;447-453.
29. Chuang L.F., Killam K.F. Jr., Chuang R.Y. Opioid dependency and T-helper functions in Rhesus monkey. In Vivo. 7:1993;159-166.
30. de Carolis C., de Sanctis G., Perricone R., Moretti C., Fabbri A., Gnessi L., Fraioli F., Fontana L. Evidence for an inhibitory role of beta-endorphin and other opioids on human total T-rosette formation. Experientia. 40:1984;738-739.
31. Donahoe R.M., Nicholson J.K.A., Madden J.J., Donahoe F., Shafer D.A., Gordon D., Bokos P., Falek A. Coordinate and independent effects of heroin, cocaine, and alcohol abuse on T-cell E-rosette formation and antigenic marker expression. Clin. Immunol. Immunopathol. 41:1986;254-264.
32. Donahoe R.M., Bueso-Ramos C., Donahoe F., Madden J.J., Falek A., Nicholson J.K.A., Bokos P. Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers. Ann. NY Acad. Sci. 496:1987;711-721.
33. Donahoe R.M., Bueso-Ramos C., Falek A., McClure H., Nicholson J.K.A. Comparative effects of morphine on leukocytic antigenic markers of monkeys and humans. J. Neurosci. Res. 19:1988;157-165.
34. Eisenstein, T.K., Taub, D.D., Adler, M.W., Rogers, T.J., 1991. The effect of morphine and DAGO on the proliferative response of murine splenocytes. In: Friedman, H., Specter, S., Klein, T.W. (Eds.), Drugs of Abuse, Immunity, and Immunodeficiency. Plenum, New York, pp. 203-209.
35. Eisenstein T.K., Meissler J.J. Jr., Rogers T.J., Geller E.B., Adler M.W. Mouse strain differences in immunosuppression by opioids in vitro. J. Pharmacol. Exp. Ther. 275:1995;1484-1489.
36. Fecho K., Dykstra L.A., Lysle D.T. Evidence of beta adrenergic receptor involvement in the immunomodulatory effects of morphine. J. Pharmacol. Exp. Ther. 265:1993;1079-1087.
37. Fecho K., Maslonek K.A., Coussons-Read M.E., Dykstra L.A., Lysle D.T. Macrophage-derived nitric oxide is involved in the depressed Concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J. Immunol. 152:1994;5845-5852.
38. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Mechanisms whereby macrophage-derived nitric oxide is involved in morphine-induced suppression of splenic lymphocyte proliferation. J. Pharmacol. Exp. Ther. 272:1995;477-483.
39. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 277:1996;633-645.
40. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 276:1996;626-636.
41. Flores L.R., Hernandez M.C., Bayer B.M. Acute immunosuppressive effects of morphine: lack of involvement of pituitary and adrenal factors. J. Pharmacol. Exp. Ther. 268:1994;1129-1134.
42. Flores L.R., Wahl S.M., Bayer B.M. Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration of lymphocyte trafficking. J. Pharmacol. Exp. Ther. 272:1995;1246-1251.
43. Foster J.S., Moore R.N. Dynorphin and related opioid peptides enhance tumoricidal activity mediated by murine peritoneal macrophages. J. Leukocyte Biol. 42:1987;171-174.
44. Freier D.O., Fuchs B.A. Morphine-induced alterations in thymocyte subpopulations of B6C3F1 mice. J. Pharmacol. Exp. Ther. 265:1993;81-88.
45. Freier D.O., Fuchs B.A. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J. Pharmacol. Exp. Ther. 270:1994;1127-1133.
46. Guan L., Townsend R., Eisenstein T.K., Adler M.W., Rogers T.J. Both T cells and macrophages are targets of κ-opioid-induced immunosuppression. Brain Behav. Immun. 8:1994;229-240.
47. Hagi K., Uno K., Inaba K., Muramatsu S. Augmenting effect of opioid peptides on murine macrophage activation. J. Neuroimmunol. 50:1994;71-76.
48. Ho W.K.K., Leung A. The effect of morphine addiction on Concanavalin A-mediated blastogenesis. Pharmacol. Res. Commun. 11:1979;413-419.
49. Johnson H.M., Smith E.M., Torres B.A., Blalock J.E. Regulation of the in vitro antibody response by neuroendocrine hormones. Proc. Natl. Acad. Sci. USA. 79:1982;4171-4174.
50. Kuis W., Villiger P.M., Leser H.-G., Lotz M. Differential processing of proenkephalin-A by peripheral blood monocytes and T-lymphocytes. J. Clin. Invest. 88:1991;817-824.
51. Lawrence D.M.P., Bidlack J.M. The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J. Pharmacol. Exp. Ther. 266:1993;1678-1683.
52. Lawrence D.M.P., El-Hamouly W., Archer S., Leary J.F., Bidlack J.M. Identification of κ-opioid receptors in the immune system by indirect immunofluorescence. Proc. Natl. Acad. Sci. USA. 92:1995;1062-1066.
53. Lefkowitz S.S., Chiang C.Y. Effects of certain abused drugs on hemolysin forming cells. Life Sci. 17:1975;1763-1768.
54. Liu Y., Blackbourn D.J., Chuang L.F., Killam K.F. Jr., Chuang R.Y. Effects of in vivo and in vitro administration of morphine sulfate upon Rhesus macaque polymorphonuclear cell phagocytosis and chemotaxis. J. Pharmacol. Exp. Ther. 263:1992;533-539.
55. Lysle D.T., Coussons M.E., Watts V.J., Bennett E.H., Dykstra L.A. Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265:1993;1071-1078.
56. Madden J.J., Donahoe R.M., Zwemer-Collins J., Shafer D.A., Falek A. Binding of naloxone to human T-lymphocytes. Biochem. Pharmacol. 36:1987;4103-4109.
57. Makman M.H., Bilfinger T.V., Stefano G.B. Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine-induced activation and chemotaxis. J. Immunol. 154:1995;1323-1330.
58. Mathews P.M., Froelich C.J., Sibbitt W.L. Jr., Bankhurst A.D. Enhancement of natural cytotoxicity by β-endorphin. J. Immunol. 130:1983;1658-1662.
59. Mazzone A., Ricevuti G., Pasotti D., Fioravanti A., Marcoli M., Lecchini S., Notario A., Frigo G.M. Peptide opioids and morphine effects on inflammatory process. Inflammation. 14:1990;717-726.
60. McDonough R.J., Madden J.J., Falek A., Shafer D.A., Pline M., Gordon D., Bokos P., Kuehnle J.C., Mendelson J. Alteration of T- and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T-lymphocytes. J. Immunol. 125:1980;2539-2543.
61. Mehrishi J.N., Mills I.H. Opiate receptors on lymphocytes and platelets in man. Clin. Immunol. Immunopathol. 27:1983;240-249.
62. Molitor T.W., Morilla A., Risdahl J.M., Murtaugh M.P., Chao C.C., Peterson P.K. Chronic morphine administration impairs cell-mediated immune responses in swine. J. Pharmacol. Exp. Ther. 260:1992;581-586.
63. Morgan E.L. Regulation of human B-lymphocyte activation by opioid peptide hormones: inhibition of IgG production by opioid receptor class (μ-, κ-, and δ-) selective agonists. J. Neuroimmunol. 65:1996;21-30.
64. Nair M.P., Laing T.J., Schwartz S. A decreased natural and antibody-dependent cellular cytotoxic activities in intravenous drug abusers. Clin. Immunol. Immunopathol. 38:1986;68-78.
65. Novick D.M., Ochshorn M., Ghali V., Croxson T.S., Mercer W.D., Chiorazzi N., Kreek M.J. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 250:1989;606-610.
66. Ochshorn-Adelson M., Novick D.M., Khuri E., Albeck H., Hahn E.F., Kreek M.J. Effects of the opioid antagonist naloxone on human natural killer cell activity in vitro. Isr. J. Med. Sci. 30:1994;679-684.
67. Oleson D.R., Johnson D.R. Regulation of human natural cytotoxicity by enkephalins and selective opiate agonists. Brain Behav. Immun. 2:1988;171-186.
68. Ovadia H., Nitsan P., Abramsky O. Characterization of opiate binding sites on membranes of rat lymphocytes. J. Neuroimmunol. 21:1989;93-102.
69. Pacifici R., Patrini G., Venier I., Parolaro D., Zuccaro P., Gori E. Effect of morphine and methadone acute treatment on immunological activity in mice: pharmacokinetic and pharmacodynamic correlates. J. Pharmacol. Exp. Ther. 269:1994;1112-1116.
70. Paterson S.J., Robson L.E., Kosterlitz H.W. Classification of opioid receptors. Brit. Med. Bull. 39:1983;31-36.
71. Pellis N.R., Harper C., Dafny N. Suppression of the induction of delayed hypersensitivity in rats by repetitive morphine treatments. Exp. Neurol. 93:1986;92-97.
72. Perez-Castrillon J.-L., Perez-Arellanos J.-L., Carcia-Palomo J.-D., Jimeniz-Lopez A., de Castro S. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacology. 23:1992;57-61.
73. Peterson P.K., Sharp B., Gekker G., Brummitt C., Keane W.F. Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J. Immunol. 138:1987;3907-3912.
74. Peterson P.K., Sharp B., Gekker G., Brummitt C., Keane W.F. Opioid-mediated suppression of interferon-γ production by cultured peripheral blood mononuclear cells. J. Clin. Invest. 80:1987;824-831.
75. Peterson P.K., Gekker G., Brummitt C., Pentel P., Bullock M., Simpson M., Hitt J., Sharp B.M. Suppression of human peripheral blood mononuclear cell function by methadone and morphine. J. Infect. Dis. 159:1989;480-487.
76. Pruett S.B., Han Y.-C., Fuchs B.A. Morphine suppresses primary humoral immune responses by a predominantly indirect mechanism. J. Pharmacol. Exp. Ther. 262:1992;923-928.
77. Puente J., Maturana P., Miranda D., Navarro C., Wolf M.E., Mosnaim A.D. Enhancement of human natural killer cell activity by opioid peptides: similar response to methionine-enkephalin and β-endorphin. Brain Behav. Immun. 6:1992;32-39.
78. Radulovic J., Miljevic C., Djergovic D., Vujic V., Antic J., von Horsten S., Jankovic B.D. Opioid receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of κ-opioid receptors. J. Neuroimmunol. 57:1995;55-62.
79. Rojavin M., Szabo I., Bussiere J.L., Rogers T.J., Adler M.W., Eisenstein T.K. Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci. 53:1993;997-1006.
80. 3H]Morphine binding is enhanced by IL-1-stimulated thymocyte proliferation. FEBS Lett. 287:1991;93-96.
81. Roy S., Ramakrishnan S., Loh H.H., Lee N.M. Chronic morphine treatment selectively suppresses macrophage colony formation in bone marrow. Eur. J. Pharmacol. 195:1991;359-363.
82. Ruff M.R., Wahl S.M., Mergenhagen S., Pert C.B. Opiate receptor-mediated chemotaxis of human monocytes. Neuropeptides. 5:1985;363-366.
83. Sedqi M., Roy S., Ramakrishnan S., Elde R., Loh H.H. Complementary DNA cloning of a μ-opioid receptor from rat peritoneal macrophages. Biochem. Biophys. Res. Comm. 209:1995;563-574.
84. Sei Y., McIntyre T., Fride E., Yoshimoto K., Skolnick P., Arora P.K. Inhibition of calcium mobilization is an early event in opiate-induced immunosuppression. FASEB J. 5:1991;2194-2199.
85. Sharp B.M., Keane W.F., Suh H.J., Gekker G., Tsukayama D., Peterson P.K. Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology. 117:1985;793-795.
86. Shavit Y., Lewis J.W., Terman G.W., Gale R.P., Liebeskind J.C. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science. 223:1984;188-190.
87. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. USA. 83:1986;7114-7117.
88. Sibinga N.E.S., Goldstein A. Opioid peptides and opioid receptors in cells of the immune system. Ann. Rev. Immunol. 6:1988;219-249.
89. 2] deltorphin I binding and pharmacological evidence for a special subtype of δ-opioid receptor on human and invertebrate immune cells. Proc. Natl. Acad. Sci. USA. 89:1992;9316-9320.
90. Stefano G.B., Digenis A., Spector S., Leung M.K., Bilfinger T.V., Makman M.H., Scharrer B., Abumrad N.N. Opiate-like substances in an invertebrate, an opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. Proc. Natl. Acad. Sci. USA. 90:1993;11099-11103.
91. Szabo I., Rojavin M., Bussiere J.L., Eisenstein T.K., Adler M.W., Rogers T.J. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J. Pharmacol. Exp. Ther. 267:1993;703-706.
92. Taub D.D., Eisenstein T.K., Geller E.B., Adler M.W., Rogers T.J. Immunomodulatory activity of μ- and κ-selective opioid agonists. Proc. Natl. Acad. Sci. USA. 88:1991;360-364.
93. Thomas P.T., Bhargava H.N., House R.V. Immunomodulatory effects of in vitro exposure to morphine and its metabolites. Pharmacology. 50:1995;51-62.
94. Thomas P.T., House R.V., Bhargava H.N. Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen. Pharmacol. 26:1995;123-130.
95. Tubaro E., Borelli G., Croce C., Cavallo G., Santiangeli C. Effect of morphine on resistance to infection. J. Infec. Dis. 148:1983;656-666.
96. Weber R.J., Pert A. The periaqueductal gray matter mediates opiate-induced immunosuppression. Science. 245:1989;188-190.
97. Weber R.J., Ikejiri B., Rice K.C., Pert A., Hagan A.A. Opiate receptor mediated regulation of the immune response in vivo. NIDA Res. Mono. Ser. 48:1987;341-348.
98. Wybran J., Appelboom T., Famaey J.-P., Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T-lymphocytes. J. Immunol. 123:1979;1068-1070.
99. Yeager M.P., Colacchio T.A., Yu C.T., Hildebrandt L., Howell A.L., Weiss J., Guyre P.M. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 83:1995;500-508.
100. Zurawski G., Benedik M., Kamb B.J., Abrams J.S., Zurawski S.M., Lee F.D. Activation of mouse T-helper cells induces abundant preproenkephalin mRNA synthesis. Science. 232:1986;772-775.